×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
🎬
Demo Video
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Demo Video
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Disease: ALS Therapeutic Landscape — Programs by Phase and Modality
disease
2,394 words
KG: ent-dise-93f3d65f
Contents
ALS Therapeutic Landscape — Programs by Phase and Modality
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
OMIM
MeSH
Wikipedia
Related Hypotheses (27)
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.55
Cryptic Exon Silencing Restoration
Score: 0.53
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47
Gap Junction Hemichannel Modulation for Controlled Mitochond
Score: 0.36
← Prev
pg 2/2
Related Analyses (26)
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Show 21 more
Related Experiments (30)
cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85
cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
validation · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Experiment Index
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel
validation · proposed · Score: 0.40
Experiment Scoring Methodology
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
PSP Therapeutic Response Monitoring and Biomarkers
mechanism · Pages share 5 hypotheses
Section 147: Telehealth and Remote Monitoring in CBS/PS
therapeutic · Pages share 5 hypotheses
Neurodegeneration
disease · Pages share 5 hypotheses
Mitochondrial DNA Mutations in Neurodegeneration
mechanism · Pages share 5 hypotheses
Integrated Stress Response Modulator Therapy in Neurode
therapeutic · Pages share 5 hypotheses
Therapeutic Modalities in Neurodegeneration
therapeutic · Pages share 5 hypotheses
Digital Therapeutic Platform for Swallowing and Droolin
clinical_trial · Pages share 5 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 5 hypotheses
Multimodal Diagnostic Algorithm for CBS and PSP
mechanism · Pages share 5 hypotheses
Integrated Stress Response in Neurodegeneration
mechanism · Pages share 5 hypotheses
Cognitive Monitoring Brain-Computer Interfaces for Neur
technology · Pages share 5 hypotheses
CRISPR Gene Editing for Neurodegeneration
therapeutic · Pages share 5 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 4 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 4 hypotheses
p-Tau Biomarker in Immunoglobulin Light Chain and Trans
biomarker · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (12 edges)
33300249
increased in
ent-dise-93f3d65f
30458231
could be beneficial in
ent-dise-93f3d65f
39317854
increase risk of
ent-dise-93f3d65f
39317854
associated with increased risk of
ent-dise-93f3d65f
35767949
are selectively vulnerable in
ent-dise-93f3d65f
34663413
is altered in
ent-dise-93f3d65f
41752118
is increasingly seen as
ent-dise-93f3d65f
34873335
causes
ent-dise-93f3d65f
24369373
has an oligogenic basis with
ent-dise-93f3d65f
24369373
are broadening the phenotype associated with
ent-dise-93f3d65f
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.